CHRS
Coherus Oncology, Inc.
$1.42
+7.58%
2026-08-21
About Coherus Oncology, Inc.
Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin IL-27. It also develops CHS-114, an investigational human afucosylated IgG1 monoclonal antibody, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME) patients with head and neck squamous cell carcinoma. It has a collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreements with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc. and Surface and Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. It also has a clinical collaboration agreement with Zumutor Biologics Inc. for the development of LOQTORZI with ZM0008 as a treatment for cancer patients. The company was formerly known as Coherus BioSciences, Inc. and changed its name to Coherus Oncology, Inc. in May 2025. The company was incorporated in 2010 and is based in Redwood City, California.
Key Fundamentals
P/E Ratio
3.00
Forward P/E
-1.90
EPS (TTM)
$-1.24
ROE
-178.4%
Revenue Growth (YoY)
39.5%
Profit Margin
-259.4%
Debt/Equity
89.05
Price/Book
3.05
Beta
0.95
Market Cap
$185.4M
Avg Volume (10D)
1.2M
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
$1.71
60D Low
$1.13
Avg Volume
993K
Latest Close
$1.42
Get breakout alerts for CHRS
Sign up for Breakout Scanner to receive daily notifications when CHRS triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial.
Coherus Oncology, Inc. (CHRS) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors CHRS daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. CHRS operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.